Dimebutic acid(Dimebutic acid) - 药物靶点：β-globin_专利_临床

概要

基本信息

药物类型

小分子化药

别名

HQK 1001、HQK-1001(Sodium)、ST-20

靶点

β-globin

作用方式

刺激剂

作用机制

β-globin刺激剂(血红蛋白β链刺激剂)

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病+ [1]

在研适应症-

非在研适应症

急性胸部综合征β地中海贫血地中海贫血

原研机构

Boston University

在研机构-

非在研机构

HemaQuest Pharmaceuticals, Inc.

Boston University

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H12O2

InChIKeyVUAXHMVRKOTJKP-UHFFFAOYSA-N

CAS号595-37-9

关联

6

项与 Dimebutic acid 相关的临床试验

NCT01601340

/ Terminated临床2期

A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease

The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.

开始日期2012-07-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

NCT01642758

/ Completed临床2期IIT

An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia

Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.
This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.

开始日期2012-05-01

申办/合作机构

Boston University

[+1]

NCT01322269

/ Completed临床2期

A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease

The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.

开始日期2011-04-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

100 项与 Dimebutic acid 相关的临床结果

登录后查看更多信息

100 项与 Dimebutic acid 相关的转化医学

登录后查看更多信息

100 项与 Dimebutic acid 相关的专利（医药）

登录后查看更多信息

422

项与 Dimebutic acid 相关的文献（医药）

2025-10-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

A novel fluorescent waterborne polyurethane-based Sm (III) ternary complex improves plant growth in light environments and promotes plant growth

作者: Wang, Ping ; Ding, Yunsheng ; Yang, Yuqing ; Pei, Shicong ; Hu, Xianhai ; Hu, Hongrui ; Li, Zhuqing ; Shao, Kaixuan ; Yang, Mingdi ; Li, Hang ; She, Xiaojun ; Zhang, Kehua

Polymeric rare earth complexes have attracted much attention due to their unique luminescence properties and application prospects.However, as an important component of polymeric rare earth complexes, Sm (III) complexes are rarely reported due to the lack of organic ligands matching the energy of Sm (III).Herein, A novel Sm(III) complexes (Sm(MPon)₃APhen) emitting red fluorescence is synthesized by using Sm(III) as the central ion and 1-(4-tert-butylphenyl)-3-(4-methoxyphenyl)-1,3-propanone (MPon) and 5-amino-1,10-phenanroline (APhen) as ligands, resp.Then, A novel waterborne polyurethane-based complex [Sm(MP)₃AP]_x-WPU with orange-red fluorescence is prepared by modified acetone method using Sm(MPon)₃APhen as the end-blocking agent.Compared with Sm(MPon)₃APhen, the fluorescence emission peak of [Sm(MP)₃AP]_x-WPU is blue-shifted, and the fluorescence intensity is significantly enhanced with the increase of the amount of Sm(MPon)₃APhen.Notably, the strongest fluorescence emission peak of [Sm(MP)₃AP]_x-WPU is located in the red light band with the highest photosynthetic absorption efficiency of plants, which could significantly improve the light environment for plant growth and promote plant growth.More importantly, [Sm(MP)₃AP]_x-WPU is water as a dispersed phase, which is particularly safe and environmentally friendly during storage, transportation and use.

2025-09-01·SYNLETT

Electromediated Alcohol-Based Passerini-Type Reaction

作者: Pan, Na ; Bachollet, Sylvestre P. J. T. ; Vitale, Maxime R. ; Simon, Alexandre ; Grimaud, Laurence

Abstract:

An electrochemical variant of the alcohol-based oxidative Passerini reaction is reported here. It relies on an indirect anodic oxidation process followed by a three-component coupling, in which TEMPO serves as a key redox mediator. This electrochemical approach permits to operate without the need for a metal catalyst nor oxygen atmosphere and allows the use of nonactivated alcohols as reaction partners. It could be applied to the preparation of good variety of α-acyloxy-carboxamides in yields ranging from 24% to 80%.

2025-05-16·ORGANIC LETTERS

Ligand-Enabled Palladium-Catalyzed β-C(sp³)–H Biarylation of Native Amides with Cyclic Diaryliodonium Salts

Article

作者: Maji, Biplab ; Das, Animesh ; Chotia, Mohit

Herein, we report a Pd-catalyzed β-C(sp³)-H biarylation of native amides using diaryliodonium salts. A pyridine-3-sulfonic acid ligand that might stabilize the substrate-bound palladium species was found to be essential for high catalytic activity. The reaction displayed a broad scope and showed excellent compatibility with diverse cyclic diaryliodonium salts and amide substrates. The retained iodo functionality on the product provides a versatile handle for further increasing molecular complexity.

1

项与 Dimebutic acid 相关的新闻（医药）

2008-12-09

·BioSpace

HemaQuest Announces Clinical Progress on New Sickle Cell Anemia Drug

SAN FRANCISCO, CA--(Marketwire - December 09, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic which the company is developing to treat hemoglobin disorders, including sickle cell anemia and beta thalassemia. The company presented the results at the annual meeting of the American Society of Hematology in San Francisco.

100 项与 Dimebutic acid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
β地中海贫血	临床2期	黎巴嫩	HemaQuest Pharmaceuticals, Inc.	2012-05-01
急性胸部综合征	临床2期	美国	HemaQuest Pharmaceuticals, Inc.	2011-04-01
急性胸部综合征	临床2期	加拿大	HemaQuest Pharmaceuticals, Inc.	2011-04-01
急性胸部综合征	临床2期	埃及	HemaQuest Pharmaceuticals, Inc.	2011-04-01
急性胸部综合征	临床2期	牙买加	HemaQuest Pharmaceuticals, Inc.	2011-04-01
急性胸部综合征	临床2期	黎巴嫩	HemaQuest Pharmaceuticals, Inc.	2011-04-01
地中海贫血	临床2期	-	Boston University	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01601340 (Pubmed \| Am J Hematol)	临床2期	镰状细胞血症	76	HQK-1001	築遞襯遞壓齋遞選艱蓋(憲遞繭夢顧網襯醖蓋壓) = The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of abdominal pain 淵選構窪餘繭憲簾獵衊 (鹹醖膚蓋鬱遞網網願鹽 ) 更多	不佳	2014-07-01
				Placebo
NCT01322269 (Pubmed \| Am J Hematol)	临床2期	镰状细胞血症	52	HQK-1001 30 mg/kg	觸積壓選遞繭築觸鹽夢(餘獵齋獵廠獵網築遞壓) = 廠鏇選鑰壓蓋艱鹽淵鹹築廠壓網鏇鹹膚壓糧艱 (簾選願製廠築壓齋選鹽, 0.8 ~ 3.2) 更多	-	2013-11-01
				HQK-1001 40 mg/kg	觸積壓選遞繭築觸鹽夢(餘獵齋獵廠獵網築遞壓) = 壓廠餘壓鹽襯繭繭願壓築廠壓網鏇鹹膚壓糧艱 (簾選願製廠築壓齋選鹽, 1.7 ~ 3.8)
NCT00842088 (Pubmed \| Am J Hematol)	临床1/2期	镰状细胞血症	24	HQK-1001 10 mg/kg	鏇餘憲鬱淵願鏇積壓憲(網糧製鹽壓憲鹽夢製窪) = 膚襯餘夢積築積糧廠製醖遞範遞鏇網鹹淵鬱遞 (選壓淵餘觸鏇壓憲範廠 ) 更多	-	2012-11-01
				HQK-1001 20 mg/kg	鏇餘憲鬱淵願鏇積壓憲(網糧製鹽壓憲鹽夢製窪) = 網窪鹽遞繭構願餘鬱糧醖遞範遞鏇網鹹淵鬱遞 (選壓淵餘觸鏇壓憲範廠 ) 更多